Analysis of the RIMDAMAL trial

Affiliations

¹ Global Health Institute, University of Antwerp, Doornstraat 331, 2610 Antwerp, Belgium. Electronic address: robert.colebunders@uantwerpen.be.
² Global Health Institute, University of Antwerp, Doornstraat 331, 2610 Antwerp, Belgium.

Comment

Robert Colebunders et al. Lancet. 2019.

. 2019 Sep 21;394(10203):1006.

doi: 10.1016/S0140-6736(19)31814-8.

¹ Global Health Institute, University of Antwerp, Doornstraat 331, 2610 Antwerp, Belgium. Electronic address: robert.colebunders@uantwerpen.be.
² Global Health Institute, University of Antwerp, Doornstraat 331, 2610 Antwerp, Belgium.

No abstract available

Comment in

Analysis of the RIMDAMAL trial - Authors' reply.
Foy BD, Rao S, Parikh S, Slater HC, Dabiré RK. Foy BD, et al. Lancet. 2019 Sep 21;394(10203):1006-1007. doi: 10.1016/S0140-6736(19)32139-7. Lancet. 2019. PMID: 31544742 No abstract available.

Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial.
Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, Parikh S, Soma DD, Sagna AB, Fournet F, Slater HC, Bougma R, Drabo F, Diabaté A, Coulidiaty AGV, Rouamba N, Dabiré RK. Foy BD, et al. Lancet. 2019 Apr 13;393(10180):1517-1526. doi: 10.1016/S0140-6736(18)32321-3. Epub 2019 Mar 14. Lancet. 2019. PMID: 30878222 Free PMC article. Clinical Trial.